Hydromorphonhydrochlorid Beta

Hydromorphone, the active ingredient in Hydromorphonhydrochlorid Beta, is an opioid analgesic presented as an oral dosage form for oral administration. It acts on central mu‑opioid receptors to produce potent analgesia and is indicated for the management of moderate to severe pain in adult patients when non‑opioid therapies are insufficient.

GNH USA supplies Hydromorphonhydrochlorid Beta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance across global markets.

Hydromorphone is an opioid analgesic used in the management of moderate to severe pain.

Acute postoperative pain: provides rapid relief after surgical procedures. Cancer‑related pain: controls persistent severe pain in oncology patients. Severe traumatic injury pain: reduces pain associated with major injuries.

Hydromorphone may cause a range of adverse reactions, from mild to life‑threatening.

Common Side Effects: - Nausea - Constipation - Drowsiness - Dizziness - Vomiting - Sweating

Serious or Rare Side Effects: - Respiratory depression - Severe hypotension - Seizures - Allergic reactions (rash, angioedema) - Dependence or addiction - Adrenal insufficiency

Careful assessment and monitoring are essential when prescribing hydromorphone. - Assess pain severity: confirm opioid therapy is appropriate for the level of pain. - Evaluate respiratory function: monitor for signs of depression, especially after dose initiation. - Check renal and hepatic function: adjust dosing if organ impairment is present. - Avoid concurrent CNS depressants: limit use of benzodiazepines, alcohol, or other sedatives. - Monitor for signs of dependence: educate patients on proper use and disposal. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Hydromorphone can interact with several drug classes, requiring vigilance.

Major Interactions (Avoid): - Other opioids: risk of additive respiratory depression. - Benzodiazepines or barbiturates: profound CNS depression. - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): increased hydromorphone plasma levels.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): reduced analgesic efficacy. - Anticholinergic agents: may exacerbate constipation. - Selective serotonin reuptake inhibitors: potential for serotonin syndrome.